FDA Approval Alert: The Need-to-Know | Brentuximab Vedotin Plus Lenalidomide/Rituximab in R/R LBCL

In February 2025, the FDA approved brentuximab vedotin plus lenalidomide and rituximab for patients with relapsed/refractory large B-cell lymphoma.

Data from the ECHELON-3 trial support the approval of the brentuximab vedotin combo in relapsed/refractory B-cell lymphoma.
FDA OKs Brentuximab Vedotin Combo in R/R Large B-Cell Lymphoma
Article
Feb 12, 2025 2:48 PM
Data from the ECHELON-3 trial support the approval of the brentuximab vedotin combo in relapsed/refractory B-cell lymphoma.